CAS: 1935-18-8; Palmitoylcarnitine

📜Dl-肉碱盐酸盐,棕榈酰氯 以 三氟乙酸 用作溶剂,化学反应 3.0H,反应生成棕榈酰肉碱
参考文献:Synthesis And Preliminary Evaluation Of Perfluoroalkylacyl Carnitines As Surfactants For Biomedical Use
标题:Synthesis And Preliminary Evaluation Of Perfluoroalkylacyl Carnitines As Surfactants For Biomedical Use
摘要:A Series Of Acyl Carnitines,4 Of Which Bearing A Terminal Perfluoroalkyl Fragment,Was Obtained From Carnitine In One Step In A High Grade Of Purity In Yields Ranging From 44-81%. The F-Alkyl Derivatives Display High Solubilities In Water,Strong Surface Activity And A Significant Emulsifying Power Towards Fluorocarbons In Water. In Spite Of Their Strong Surface Activity,All The Biocompatibility Tests Performed (In Vitro Toxicity On Namalva Cells Cultures,Hemolysis On Human Red Blood Cells,And Iv Injections In Mice) Indicate A Significantly Better Biological Tolerance Than Their Hydrocarbon Analogs,Provided The F-Alkyl Moiety Is Larger Than The Alkyl Moiety In The Hydrophobic Tail.
Doi:10.1016/0223-5234(91)90138-D

专利信息

专利号:US-6149924-A
优先权日:1998-07-20
标题 :Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
发明人：PAUL HARBHAJAN S
权利人:BIOMED RES & TECHNOLOGIES INC
摘要:Increased production of skin lipids, increased barrier function, hydrogen peroxide neutralization, prevention of loss of the natural moisturizing factor from the stratum corneum and moisturization of the skin is provided by a topically applicable composition which includes one or more components selected from the group consisting of branched chain amino acids, derivatives of branched chain amino acids and mixtures thereof, which one or more components are capable of being catabolized in epidermal cells to form lipid precursors for epidermal lipid synthesis. The composition can also include one or more enzyme activators which increase the rate of catabolism of the one or more components.

专利号:US-2024216412-A1
优先权日:2022-11-22
标 题 :Oxidized nicotinamide adenine dinucleotide (nad+) precursor treatment for heart failure alleviation independent of mitochondrial protein deacetylation
发明人：TIAN RONG; WALKER MATTHEW
权利人:UNIV WASHINGTON
摘要:The current disclosure provides provides boosting intracellular NAD + with nicotinamide riboside chloride (NR) to protect from cardiac dysfunction, NR being a natural NAD + precursor that bypasses nicotinamide phosphoribosyltransferase (NAMPT) to stimulate intracellular NAD + synthesis.

专利号:US-2020330400-A1
优先权日:2016-03-16
标 题:Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
发明人：GESTA STEPHANE; DIERS ANNE R; DADALI-ABEL TULIN
权利人:BERG LLC
摘要:Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 compositions and at least one fatty acid metabolism inhibitor. In one embodiment, the CoQ10 compositions are lipid-containing compositions. The fatty acid metabolism inhibitor may be an inhibitor of fatty acid synthesis, storage, transport or degradation. The fatty acid metabolism inhibitor may also be a modulator of fatty acid structure, for example a fatty acid desaturase or elongase. The fatty acid inhibitor may inhibit any molecule involved in fatty acid metabolism, such as fatty acid synthase (FASN), carnitine palmitoyltransferase 1 (CPT-1), long-chain 3-ketoacyl-CoA thiolase, or stearoyl-CoA desaturase-1 (SCD-1). In embodiments, the fatty acid metabolism inhibitor may be C75, Etomoxir, trimetazidine or A939572.

专利号:WO-2023144235-A1
优先权日:2022-01-27
标 题 :Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
发明人：CANAUD GUILLAUME; LADRAA SOPHIA
权利人:INST NAT SANTE RECH MED; ASSIST PUBLIQUE HOPITAUX PARIS APHP; CENTRE NAT RECH SCIENT; UNIV PARIS CITE
摘要:Using a unique tool of PROS, they demonstrate that PIK3CA mutation leads to GLUT4 membrane accumulation with a negative feedback loop on insulin secretion, a burst of liver IGFBP1 synthesis with IGF1 sequestration and low circulating levels. They further show that AKT2 drives a large part of the phenotype. In addition, they demonstrate for the first time that a single PIK3CA mutation induces metabolic reprogramming with the Warburg effect and protein and lipid synthesis—hallmarks of cancer cells—in vitro, in vivo and in patients. They finally show that alpelisib, an approved PIK3CA inhibitor in oncology, is efficient at preventing and improving PIK3CA-adipose tissue overgrowth and reversing metabolomic anomalies in both animal models and patients. Accordingly, the present invention relates to an in vitro method for monitoring the efficiency of a PI3K inhibitor treatment in a subject in need thereof comprising the step of determining the level of at least one metabolite selected in the group consisting of cis-aconitate, succinic acid, 5-methylcytosine, acetyl-carnitine, acetyl-lysine, argininosuccinate, betaine, butyric acid, carnitine, creatine, glucose, glycine, hexanoyl-carnitine, L-fucose, lactate, L-dihydroorotic acid, linolenic acid, nicotinamide N-oxide, palmitoyl-carnitine, panthotenate, pyruvate, quinolinic acid, tryptophan, urate, in a biological sample obtained from the subject.

专利号:WO-2024231384-A1
优先权日:2023-05-10
标题:Compositions for treating senescence related disease
发明人：PENDE MARIO; FUMAGALLI STEFANO
权利人:INST NAT SANTE RECH MED; CENTRE NAT RECH SCIENT; UNIV PARIS CITE
摘要:Inventors have identified glycerol-3-phosphate (G3P) and phosphoethanolamine (PEtn) metabolism as potent regulators of the senescent program at the nexus of TAG and PL metabolism. They show that Glycerol kinase (GK) and Phosphate Cytidylyltransferase 2 Ethanolamine (Pcyt2) activities, which catalyse regulatory steps in TAG and PL synthesis impact G3P and PEtn levels in a homeostatic fashion controlling the senescence program. Finally, they provide evidence that pharmacological inhibitors of GK activity act senomorphic, thus suggesting a novel therapeutic target for interventions in age-related diseases and cancer. The present invention relates to a method for treating senescence related disease in a subject in need thereof comprising administering said subject with a therapeutically effective amount of a modulator of Glycerol kinase (GK), Glycerol 3 phosphate phosphatase (G3PP), Ethanolamine-Phosphate Phospho-Lyase (ETNPPL) and/or Phosphate Cytidylyltransferase 2 (PCYT2).

专利号:CN-112851747-B
优先权日:2019-11-12
标题:A kind of polypeptide synthesis method containing quaternary ammonium base derivative modification